1. The Market Structure Forcing Manufacturing Innovation The global generic drug market generated approximately $245 billion in 2020 and is […]

1. The Strategic Stakes: Why Your CDMO Model Choice Determines IP Value, Not Just Cost The question most pharmaceutical executives

Introduction: The Strategic Imperative of Project Management in the Modern CDMO Ecosystem The pharmaceutical and biotechnology industries operate at the

Generic drug development is a precision game, not a volume game. The companies pulling consistent margin out of a commoditized

Generic drugs fill 91% of U.S. prescriptions but account for only 18% of total drug spending. That gap, roughly $400

A deep-dive reference for oral solid dosage strategy, patent lifecycle management, and formulation-based value creation. 1. The Multi-Unit Architecture: Why

Generic drug development runs on borrowed science. The molecule has already been discovered, the clinical benefit already proven. The scientific

The active pharmaceutical ingredient gets the press release. Excipients get the patent that keeps generic companies out for a decade.

Target Audience: Pharma/biotech IP counsel, ANDA portfolio managers, R&D leads, CMC directors, and institutional investors tracking complex generics pipelines. 1.